Elixir Pharmaceuticals Inc. has revealed fresh data about the use of ghrelin antagonism to possibly treat type 2 diabetes .
Elixir focuses primarily on developing new drugs and treatments to aid metabolic disease. In turn, their solutions can aid people with type 2 diabetes. Metabolic disease is a major contributory factor to the type 2 diabetes epidemic that is sweeping the globe.
The discovery involves a metabolic regulator called ghrelin. The hormone, which occurs naturally, stimulates the appetite and the level of food consumption. Elixir scientists presented their findings at a conference in America.
The team examined the affects of ghrelin on mice. The Chief Scientific Officer of Elixir, Peter DiStefano, said: “Ghrelin represents one of the most exciting and well-characterized targets in obesity and diabetes research today because of its central role in regulating metabolism . These preclinical data provide compelling evidence and further confirm ghrelin’s role in metabolic regulation. Importantly, our scientists have shown pharmacologic inhibition of the ghrelin receptor results in a reduction in fasting glucose levels, reduction in insulin resistance, and weight loss .”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…